Proteasome Inhibitors Versus E3 Ligase Inhibitors for Cancer Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Proteasome Inhibitors Versus E3 Ligase Inhibitors for Cancer Therapy

Published:2014 Issue: Volume: Page:291-316
ISSN:2196-5501
Container-title:Resistance to Targeted Anti-Cancer Therapeutics
language:
Short-container-title:

Author:

Mattern Michael R.,Eddins Michael J.,Agarwal Saket,Sterner David E.,Kodrasov Matthew P.,Kumar K. G. Suresh,Wu Jian,Nicholson Benjamin

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-06752-0_12

Reference128 articles.

1. Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7(1):9–16

2. McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11(4–5):164–179

3. Anderson KC (2013) Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Canc Netw 11(5 suppl):676–679

4. Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5):417–421

5. Lopez-Girona A et al (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11):2326–2335

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic retinopathy its genetics and single nucleotide polymorphism associated with multi-ethnic cohort – A review;Materials Today: Proceedings;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3